Press

Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders

Aug 20 • 3 min read

Vancouver, Canada – Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (‘Clearmind’ or the ‘company’), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the submission of a patent application under the international Patent Cooperation Treaty (‘PCT’) as part of the company’s ongoing collaboration with the with Yissum Research…

Hempacco Co., Inc. Announces Board and Committee Appointments

Aug 16 • 3 min read

On August 9, 2024, the Board of Directors of Hempacco Co., Inc. appointed Paul Glavine and Harrison Newlands as members of the Board of the Company to fill two vacancies on the Board. Mr. Glavine and Mr. Newlands are both considered ?independent? directors under relevant SEC and Nasdaq rules, and they will each serve with…

Optimi Health Completes Inaugural Export of MDMA Capsules to Australia for PTSD Treatment

Aug 16 • 5 min read

Vancouver, British Columbia–(Newsfile Corp. – August 16, 2024) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a GMP-approved, Health Canada-licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, is pleased to announce it has completed the inaugural export of it’s GMP-validated MDMA capsules to Australia for the treatment…

Filament Health Announces Second Quarter 2024 Financial Results and Operational Highlights

Aug 15 • 2 min read

VANCOUVER, BC, Aug. 14, 2024 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, released its second quarter financial results and operational highlights for the period ended June 30, 2024. “This quarter we were proud to announce a significant milestone – Health Canada and US FDA authorization of a Phase…

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

Aug 15 • 2 min read

SARASOTA, FL, Aug. 14, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced a new agreement with Sever Pharma Solutions for scale-up extrusion of the Company’s SP-26 ketamine-loaded implant therapeutic targeting fibromyalgia and…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441